FDA/EMA join arms to streamline generic bioequivalence study inspections
This article was originally published in Scrip
Executive Summary
The FDA and the EMA plan to start the new year by joining forces to streamline information sharing on inspections of bioequivalence studies conducted and planned for generic drug applications, the agencies revealed on 18 December.